IL313254A - Coronavirus vaccine formulations - Google Patents

Coronavirus vaccine formulations

Info

Publication number
IL313254A
IL313254A IL313254A IL31325424A IL313254A IL 313254 A IL313254 A IL 313254A IL 313254 A IL313254 A IL 313254A IL 31325424 A IL31325424 A IL 31325424A IL 313254 A IL313254 A IL 313254A
Authority
IL
Israel
Prior art keywords
vaccine formulations
formulations against
against corona
corona
vaccine
Prior art date
Application number
IL313254A
Other languages
English (en)
Hebrew (he)
Inventor
Michael J Massare
Gale Smith
Jing-Hui Tian
Original Assignee
Novavax Inc
Michael J Massare
Gale Smith
Tian jing hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc, Michael J Massare, Gale Smith, Tian jing hui filed Critical Novavax Inc
Publication of IL313254A publication Critical patent/IL313254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL313254A 2021-11-30 2022-11-30 Coronavirus vaccine formulations IL313254A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163284497P 2021-11-30 2021-11-30
US202163292120P 2021-12-21 2021-12-21
US202163293519P 2021-12-23 2021-12-23
US202263332530P 2022-04-19 2022-04-19
US202263367678P 2022-07-05 2022-07-05
PCT/US2022/080700 WO2023102448A2 (en) 2021-11-30 2022-11-30 Coronavirus vaccine formulations

Publications (1)

Publication Number Publication Date
IL313254A true IL313254A (en) 2024-08-01

Family

ID=86613115

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313254A IL313254A (en) 2021-11-30 2022-11-30 Coronavirus vaccine formulations

Country Status (10)

Country Link
US (1) US20250025549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440613A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024545420A (cg-RX-API-DMAC7.html)
KR (1) KR20240125935A (cg-RX-API-DMAC7.html)
AU (1) AU2022399829A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241118A1 (cg-RX-API-DMAC7.html)
IL (1) IL313254A (cg-RX-API-DMAC7.html)
MX (1) MX2024006589A (cg-RX-API-DMAC7.html)
TW (1) TW202332685A (cg-RX-API-DMAC7.html)
WO (1) WO2023102448A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116622651A (zh) * 2022-03-25 2023-08-22 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 缺失Furin酶切位点的新冠病毒株及其应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024089638A1 (en) * 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021214064A1 (en) * 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
WO2021154763A1 (en) * 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) * 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
JP2025500433A (ja) * 2021-12-23 2025-01-09 ノババックス,インコーポレイテッド 抗SARS-CoV-2スパイク(S)抗体およびCOVID-19の処置におけるそれらの使用
IL318555A (en) * 2022-07-26 2025-03-01 Novavax Inc ACE2 Blockade Test to Assess the Immunogenicity of Vaccines
US20260028644A1 (en) * 2022-07-26 2026-01-29 Novavax, Inc. Pseudovirus based neutralization assay for evaluating vaccine immunogenicity

Also Published As

Publication number Publication date
EP4440613A4 (en) 2026-02-11
WO2023102448A3 (en) 2023-08-31
EP4440613A2 (en) 2024-10-09
KR20240125935A (ko) 2024-08-20
US20250025549A1 (en) 2025-01-23
JP2024545420A (ja) 2024-12-06
MX2024006589A (es) 2024-08-20
AU2022399829A1 (en) 2024-06-27
WO2023102448A2 (en) 2023-06-08
CA3241118A1 (en) 2023-06-08
TW202332685A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
EP4135847A4 (en) Coronavirus vaccine
SI3585803T1 (sl) Formulacije konjugiranega pnevmokoknega cepiva
EP4159234A4 (en) VACCINE AGAINST SARS-COV-2
EP4313143A4 (en) Coronavirus vaccine formulations
EP3989959A4 (en) TRANSDERMAL FORMULATIONS
SI3927315T1 (sl) Okusne formulacije
IL285674A (en) Pharmaceutical formulations
EP4387657A4 (en) Lipid nanoparticle formulations
EP4448770A4 (en) EFFICIENT VACCINE
EP4440613A4 (en) CORONAVIRUS VACCINE FORMULATIONS
EP3955910A4 (en) DELAYED RELEASE FORMULATION
EP4387592A4 (en) VACCINE COMPOSITIONS
EP4013441A4 (en) LARAZOTIDE FORMULATIONS
EP4185323A4 (en) AAV5 VACCINE AGAINST SARS-CoV-2
DK3781132T3 (da) Apixabanformuleringer
EP4125430A4 (en) SWEETENER FORMULATIONS
CR20220587A (es) Formulaciones farmacéuticas
DK3911298T3 (da) Formuleringer
EP4284362A4 (en) Formulations
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
IL307342A (en) Formulations of apremilast
IL287729A (en) Antibiotic cannabinoid-terpene formulations
EP4099999C0 (en) DOCETAXEL FORMULATIONS
IL310652A (en) Formulations of radiprodil
EP4188088A4 (en) Formulations